Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...

Wall Street analysts expect Royalty Pharma (RPRX) to post quarterly earnings of $0.99 per share in its upcoming report, which indicates a year-over-year increase of 1%. Revenues are expected to be ...